永安药业(002365) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was CNY 413,233,470.50, representing a 33.26% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was CNY 35,182,276.78, a significant increase of 69.69% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 32,065,703.57, up 146.31% compared to the same period last year[3]. - Basic earnings per share for Q3 2021 were CNY 0.13, an increase of 85.71% year-on-year[3]. - The total operating revenue for the period reached RMB 1,125,358,543.96, an increase of 26.2% compared to RMB 891,403,445.31 in the previous period[22]. - The net profit for Q3 2021 was CNY 89,676,826.97, a decrease of 29.5% compared to CNY 127,276,797.22 in Q3 2020[23]. - Operating profit for Q3 2021 was CNY 100,684,604.67, down 30.6% from CNY 144,995,668.43 in the same period last year[23]. - The total comprehensive income for Q3 2021 was CNY 89,558,557.93, down 29.3% from CNY 126,646,692.12 in Q3 2020[24]. - Basic and diluted earnings per share for Q3 2021 were both CNY 0.29, a decrease from CNY 0.40 in Q3 2020[24]. Cash Flow and Investments - The operating cash flow for the year-to-date period was CNY 13,223,888.88, showing a decrease of 90.21% compared to the previous year[3]. - Net cash flow from operating activities decreased by 90.21% to CNY 13,223,888.88, impacted by rising material prices and shipping costs[10]. - The cash flow from operating activities in Q3 2021 was CNY 13,223,888.88, a significant decrease of 90.2% compared to CNY 135,121,709.95 in Q3 2020[27]. - The total investment cash inflow for Q3 2021 was CNY 756,485,282.76, compared to CNY 628,231,969.39 in Q3 2020, marking an increase of 20.4%[27]. - The net cash flow from financing activities in Q3 2021 was -CNY 140,529,002.14, a decrease from CNY 68,397,257.94 in Q3 2020[28]. - The net cash flow from investing activities decreased by 153.56% to CNY 128,632,637.28, mainly due to a decline in the scale of financial products redeemed[10]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,249,068,923.77, reflecting a 3.94% increase from the end of the previous year[3]. - The company's total assets as of September 30, 2021, were RMB 2,249,068,923.77, compared to RMB 2,163,733,031.71 at the end of 2020[19]. - The company's total liabilities decreased to RMB 328,935,792.31 from RMB 349,924,967.11 in the previous period[20]. - The company's equity attributable to shareholders was CNY 1,829,994,684.89, which is a 4.23% increase compared to the end of the previous year[3]. - The company's equity attributable to shareholders reached RMB 1,829,994,684.89, an increase from RMB 1,755,713,012.60 in the previous period[20]. - Short-term borrowings decreased by 83.65% to CNY 20,000,000.00 as a result of repayment of bank loans[9]. Operational Metrics - Operating costs increased by 33.29% to CNY 815,967,807.25 due to rising raw material prices and increased production and sales volume[9]. - Total profit decreased by 30.91% to CNY 98,623,879.90, primarily due to a reduction in operating profit[9]. - The company reported a 42.18% decrease in income tax expenses to CNY 8,947,052.93, reflecting a decrease in total profit[9]. - Research and development expenses for Q3 2021 amounted to CNY 39,209,392.77, up 21.9% from CNY 32,179,141.38 in Q3 2020[23]. Inventory and Receivables - Accounts receivable increased by 81.61% to CNY 229,017,894.38 due to increased sales and extended collection periods caused by international shipping delays[8]. - Inventory increased by 31.48% to CNY 107,380,288.90 due to preparations for the Double 11 e-commerce promotion[9]. - The company’s inventory increased to RMB 107,380,288.90 from RMB 81,667,741.08 in the previous period[18]. - The company reported a 138.11% increase in prepayments to CNY 56,387,986.98, primarily due to material stocking during holidays[8]. - Other current assets surged by 1057.44% to CNY 8,177,293.36 primarily due to the consolidation of Qian'an Hydrogen Energy and an increase in VAT credits[9]. Investments and Acquisitions - Long-term equity investments rose by 230.94% to CNY 116,726,768.95 as a result of increased investment in Wuhan Low Dimension[9]. - The company acquired 60% of Zhongji Hydrogen Energy for a total price of RMB 36 million, making it a controlling subsidiary[14]. - The company invested RMB 80 million to acquire 40% of Wuhan Low Dimensional, completing the registration of the equity transfer[15]. Legal Matters - The company completed the withdrawal of a patent infringement lawsuit in the U.S., ending the litigation[15].